Foresee Pharmaceuticals Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Foresee Pharmaceuticals Co., Ltd.
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
New drugs from Eli Lilly, Pfizer, Janssen, GSK, Arvelle, BioCryst, Diurnal and Myovant are also among the latest products the European Medicines Agency is evaluating for potential pan-EU approval.
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
Foresee is seeking a US commercial partner for the long-acting leuprolide it has just filed in the US; Sun has launched ready-to-infuse gemcitabine in the US as the first in an intended line of pre-mixed cancer therapies.
- Drug Delivery
- Controlled Release
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- Foresee Pharmaceuticals Inc.